COASY

COASY encodes the bifunctional CoA synthase that catalyzes the terminal steps of de novo coenzyme A biosynthesis, an activity essential for normal development, mitochondrial function, and signaling across multiple tissues (PMID:27892483, PMID:30089828). Its enzymatic role is established directly in patient fibroblasts, where biallelic loss-of-function variants abolish CoA synthase protein and activity and cause a lethal pontocerebellar hypoplasia phenotype (PMID:30089828); in zebrafish, loss of coasy depletes CoA and dorsalizes the embryo through reduced BMP receptor expression and BMP pathway activity, with rescue by exogenous CoA or wild-type but not mutant human COASY demonstrating that the developmental phenotypes are specifically attributable to CoA biosynthesis (PMID:27892483). COASY deficiency compromises mitochondrial integrity: loss diminishes assembly and activity of electron transport chain complexes I and III, lowers ATP production, and promotes mitochondrial DNA release and apoptosis (PMID:39985665), and patient cells show impaired respiration with selectively reduced mitochondrial 4'-phosphopantetheinylated proteins despite preserved bulk CoA, indicating that COASY function is particularly critical for mitochondrial protein modification (PMID:38750253). In the nervous system, neuron-specific Coasy deletion in mice recapitulates CoPAN features including neurodegeneration, iron dyshomeostasis, and neuroinflammation, the last of which is a pathogenic component downstream of CoA deficiency and is attenuated by the PPARγ agonist leriglitazone (PMID:41985770). Beyond its canonical biosynthetic role, COASY directly binds the PI3K regulatory subunit PI3K-P85α to promote AKT/mTOR phosphorylation, cell survival, and DNA double-strand break repair (PMID:31704889), and influences hepatic lipid droplet cholesterol homeostasis upstream of diet-induced steatohepatitis [PMID:bio_10.1101_2025.02.25.640203].

1. 2016 High

   Established that COASY's developmental role operates through CoA biosynthesis rather than a CoA-independent function, by showing that loss-of-function phenotypes track with CoA depletion and require enzymatically functional protein for rescue.

   Evidence Morpholino knockdown in zebrafish with CoA quantification, BMP pathway activity assays, and rescue with exogenous CoA and WT vs. mutant human COASY

   PMID:27892483

   Open questions at the time

   • Does not define how CoA depletion mechanistically reduces BMP receptor expression
   • Mammalian developmental requirement not addressed here
2. 2018 High

   Linked COASY loss-of-function directly to human disease by demonstrating that biallelic variants abolish CoA synthase enzymatic activity and protein in patient cells, causing lethal pontocerebellar hypoplasia.

   Evidence Whole-exome sequencing, RNA splice analysis, immunoblot, and CoA synthase activity assays in patient fibroblasts from two families

   PMID:30089828

   Open questions at the time

   • Does not resolve which downstream CoA-dependent processes drive the neurodevelopmental phenotype
   • Tissue selectivity of the phenotype unexplained
3. 2019 Medium

   Identified a non-canonical role beyond CoA biosynthesis, showing COASY physically engages PI3K-P85α to drive AKT/mTOR signaling, survival, and DNA repair, and thereby modulates radiosensitivity.

   Evidence Reciprocal Co-IP, shRNA knockdown with AKT/mTOR phosphorylation and DNA repair readouts, and xenograft assays

   PMID:31704889

   Open questions at the time

   • Whether the PI3K interaction depends on CoA synthase catalytic activity is unresolved
   • Structural basis of COASY-P85α binding unknown
4. 2020 Medium

   Tested whether CoA biosynthesis is rate-limiting for cancer cell behavior, finding that robust COASY knockdown halves CoA but does not impair TNBC proliferation or migration, implying compensatory CoA maintenance.

   Evidence Stable inducible shRNA knockdown with CoA quantification and proliferation/migration assays across multiple constructs and cell lines

   PMID:32828275

   Open questions at the time

   • Compensatory mechanisms maintaining CoA not identified
   • Does not assess in vivo or metabolic stress conditions
5. 2024 Medium

   Refined the disease mechanism by showing COASY is critical for mitochondrial protein 4'-phosphopantetheinylation and respiration even when bulk CoA appears normal, shifting emphasis from total CoA pools to a specific mitochondrial modification.

   Evidence Respirometry, quantification of 4'-phosphopantetheinylated proteins, and RNA-seq in patient fibroblasts

   PMID:38750253

   Open questions at the time

   • The identity of the affected phosphopantetheinylated mitochondrial proteins is not defined
   • Mechanistic link from reduced modification to respiratory defect not established
6. 2025 Medium

   Defined the mitochondrial degeneration mechanism, showing COASY loss impairs ETC complex I and III assembly/activity, lowers ATP, and triggers mtDNA release and apoptosis.

   Evidence Drosophila muscle and brain knockdown with mitochondrial integrity, ETC complex, ATP, and mtDNA assays

   PMID:39985665

   Open questions at the time

   • Does not establish whether complex defects are direct consequences of impaired phosphopantetheinylation
   • mtDNA release trigger not mechanistically dissected
7. 2025 Medium

   Proposed a CoA-dependent signaling axis in which COASY controls HIF-1α/2α stability via CoAlation of the UBFD1 PH domain, scaffolding HIFα for proteasomal degradation independently of oxygen sensing.

   Evidence Proximity-labelling proteomics (BioID), HIFα stability assays under normoxia, knockdown/overexpression, and in vivo metastasis assay (preprint)

   PMID:bio_10.1101_2025.06.18.660436

   Open questions at the time

   • Preprint, not yet peer-reviewed and from a single lab
   • Direct demonstration that UBFD1 CoAlation is required in vivo is incomplete
   • Generality beyond TNBC unknown
8. 2025 Medium

   Extended COASY's physiological reach to hepatic lipid metabolism, placing it upstream of lipid droplet cholesterol accumulation and diet-induced steatohepatitis.

   Evidence ASO-mediated Coasy knockdown in mice with lipid droplet cholesterol quantification, steatohepatitis/fibrosis histopathology, and dietary cholesterol rescue (preprint)

   PMID:bio_10.1101_2025.02.25.640203

   Open questions at the time

   • Preprint, not yet peer-reviewed and from a single lab
   • Molecular link between CoA biosynthesis and lipid droplet cholesterol not defined
9. 2026 Medium

   Identified neuroinflammation as a tractable pathogenic component of CoA-deficiency neurodegeneration and a candidate therapeutic node.

   Evidence Inducible neuron-specific Coasy knockout mice with behavioral, histopathological, and iron readouts plus leriglitazone (PPARγ agonist) intervention

   PMID:41985770

   Open questions at the time

   • Mechanism linking CoA loss to iron dyshomeostasis not resolved
   • Whether leriglitazone acts on neurons or glia is unclear

• It remains unresolved how COASY's catalytic CoA-synthesizing function is mechanistically coupled to its signaling roles (PI3K-AKT-mTOR, HIFα/UBFD1) and to tissue-selective phenotypes, and whether these depend on CoA, CoAlation, or CoA-independent protein interactions.
• No structural model integrating catalytic and scaffolding activities
• CoAlation substrate repertoire incompletely mapped
• Basis of tissue selectivity (neuron vs. liver vs. tumor) unknown